<DOC>
	<DOCNO>NCT00255918</DOCNO>
	<brief_summary>This study determine effectiveness drug , dimethoxbenzylidene anabaseine , produce beneficial effect similar nicotine individual schizophrenia .</brief_summary>
	<brief_title>Investigation Drug Dimethoxbenzylidene Anabaseine Treating Schizophrenia Patients</brief_title>
	<detailed_description>Schizophrenia chronic severe brain disorder significantly impact quality life . It characterize delusion , paranoia , disorder thinking . The cause schizophrenia yet determine . However , many treatment , include drug therapy cognitive behavioral therapy , may help alleviate symptom condition . Nicotinic receptor involve number biological process ; numerous throughout central peripheral nervous system diverse structure expression . Genetic neurobiological research identify decreased expression a7 nicotinic receptor element schizophrenia relate poor psychosocial outcome . Data indicate drug therapy may reduce deficit receptor expression . Nicotine find stimulate a7 nicotinic receptor ; however , physiological dependence associate nicotine make undesirable option . Dimethoxbenzylidene anabaseine ( DMXB-A ) stimulate a7 nicotinic receptor ; advantage include easy oral administration lack dependence-causing effect . This study determine whether DMXB-A safely effectively stimulate a7 nicotinic receptor schizophrenia patient reduce neurobiological symptom . This study last 6 week . Participants study visit week duration study . During visit , participant randomly assign receive either DMXB-A placebo . An electrocardiogram ( EKG ) measure heart function participant participant ' blood pressure measure . After first dose either DMXB-A placebo , participant receive second dose 2 hour later . An evoked potential test , measure brain 's response stimulus , perform dos . Neuropsychological test , verbal reason visual retention , perform follow second dose either DMXB-A placebo .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>3- ( 2,4-dimethoxybenzylidene ) anabaseine</mesh_term>
	<criteria>Diagnosis schizophrenia History cardiovascular illness neurological illness schizophrenia Current substance abuse , include nicotine History clozapine use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Evoked Potentials</keyword>
	<keyword>3- ( 2,4-dimethoxybenzylidene ) anabaseine</keyword>
	<keyword>DMXB-A</keyword>
	<keyword>Receptors , Nicotinic</keyword>
</DOC>